| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Over the last 12 months, insiders at enGene Holdings Inc. have bought $0 and sold $0 worth of enGene Holdings Inc. stock.
On average, over the past 5 years, insiders at enGene Holdings Inc. have bought $4.03M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 561,797 shares for transaction amount of $5M was made by Forbion Growth Opportunities Fund I Cooperatief U.A. (10 percent owner) on 2024‑10‑30.
| 2024-10-30 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 561,797 1.1339% | $8.90 | $5M | -38.08% | ||
| 2024-10-08 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 800 0.0012% | $6.60 | $5,278 | -24.30% | ||
| 2024-10-07 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 11,844 0.0176% | $6.55 | $77,531 | -19.66% | ||
| 2024-10-04 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 5,997 0.0089% | $6.54 | $39,242 | -19.31% | ||
| 2024-10-03 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 5,769 0.0085% | $6.48 | $37,397 | -17.31% | ||
| 2024-10-02 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 10,153 0.0147% | $6.37 | $64,697 | -16.80% | ||
| 2024-10-01 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 35,279 0.0515% | $6.44 | $227,158 | -17.43% | ||
| 2024-09-30 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 341,332 0.4906% | $6.34 | $2.16M | -18.56% | ||
| 2024-09-27 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 41,639 0.0564% | $5.97 | $248,699 | -11.57% | ||
| 2024-09-27 | Cooper Ronald Harold Wilfred | Chief Executive Officer | 10,000 0.0129% | $5.70 | $57,000 | -11.57% | ||
| 2023-12-29 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 10,020 0.0206% | $9.06 | $90,771 | -6.28% | ||
| 2023-12-28 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 5,050 0.0088% | $7.69 | $38,827 | +6.66% | ||
| 2023-12-27 | Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 2,750 0.0045% | $7.17 | $19,711 | +17.85% |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | 10 percent owner | 3032430 5.9233% | $29.66M | 12 | 0 | <0.0001% |
| Cooper Ronald Harold Wilfred | Chief Executive Officer | 10000 0.0195% | $97,800.00 | 1 | 0 | <0.0001% |
$3,611,891 | 113 | 13.40% | $578.31M | |
$860,541,348 | 82 | -5.10% | $518.06M | |
$63,049,419 | 31 | 2.87% | $534.69M | |
$4,306,464 | 21 | 37.34% | $457.78M | |
$112,238,340 | 19 | 39.16% | $482.32M | |
$2,516,932 | 19 | -15.78% | $461.52M | |
$46,858,891 | 18 | -11.58% | $573.63M | |
$3,556,951 | 18 | 9.64% | $530.03M | |
enGene Holdings Inc. Common Stock (ENGN) | $8,069,667 | 13 | -13.57% | $500.69M |
$19,167,169 | 10 | 28.48% | $575.2M | |
$75,069,528 | 10 | 19.77% | $557.19M | |
$88,549,962 | 5 | -16.91% | $476.92M | |
$79,246,559 | 5 | -27.73% | $482.26M | |
$58,352 | 4 | -43.78% | $499.96M | |
$144,224 | 4 | 21.31% | $478.53M | |
$1,746,565 | 4 | -29.05% | $528.02M | |
$10,104,842 | 3 | 5.45% | $460.55M | |
$2,857,000 | 2 | -5.23% | $494.27M | |
$300,016 | 1 | -50.33% | $548.94M |
| Increased Positions | 15 | +35.71% | 7M | +16.25% |
| Decreased Positions | 13 | -30.95% | 6M | -14.26% |
| New Positions | 8 | New | 6M | New |
| Sold Out Positions | 4 | Sold Out | 727,483 | Sold Out |
| Total Postitions | 44 | +4.76% | 41M | +1.98% |
| Fcpm Iii Services B.V. | $85,248.00 | 14.38% | 9.63M | 0 | 0% | 2025-09-30 |
| Vr Adviser, Llc | $44,661.00 | 7.53% | 5.05M | 0 | 0% | 2025-09-30 |
| Kynam Capital Management, Lp | $44,198.00 | 7.45% | 4.99M | 0 | 0% | 2025-09-30 |
| Blue Owl Capital Holdings Lp | $29,011.00 | 4.89% | 3.28M | -450,000 | -12.07% | 2025-09-30 |
| Cormorant Asset Management, Lp | $20,564.00 | 3.47% | 2.32M | 0 | 0% | 2025-09-30 |
| Braidwell Lp | $20,057.00 | 3.38% | 2.27M | +2M | New | 2025-09-30 |
| Deep Track Capital, Lp | $19,818.00 | 3.34% | 2.24M | -2M | -50.87% | 2025-09-30 |
| Perceptive Advisors Llc | $18,561.00 | 3.13% | 2.1M | +2M | New | 2025-09-30 |
| Point72 Asset Management, L.P. | $10,694.00 | 1.8% | 1.21M | +100 | +<0.01% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $10,243.00 | 1.73% | 1.16M | +1M | New | 2025-09-30 |